AAOS 2019: OSSO VR Develops VR Training Tool For Smith & Nephew's NAVIO Robot, And More On Orthorobotics

Osso VR partnered with Smith & Nephew to develop a VR training tool that will be showcased at this year's American Association of Orthopedic Surgeons' (AAOS) conference, taking place in Las Vegas from March 12-16. Orthopedic robotic systems continue to draw high interest from surgeons. The recent US FDA clearance of Zimmer Biomet's ROSA total knee replacement system will add competition to the current market dominated by Stryker's MAKO and Smith & Nephew's NAVIO.

hip replacement - Image

Virtual training company [Osso VR] is kicking off this year's American Association of Orthopedic Surgeons' (AAOS) annual conference in Las Vegas by announcing a new partnership with Smith & Nephew PLC to develop a module to train surgeons on its NAVIO surgical system.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By 

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

 

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

More from Medtech Insight